Progressive Pulmonary Fibrosis Market
Progressive Pulmonary Fibrosis Market Infographics

Progressive Pulmonary Fibrosis

Progressive pulmonary fibrosis (PPF), also referred as progressive fibrosing interstitial lung disease (PF-

ILD), defines the continuing worsening of any preexisting ILD of known or unknown etiology despite appropriate treatment. Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease, such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.


Progressive Pulmonary Fibrosis Epidemiology Segmentation in the 7MM


  • Total Prevalent Cases
  • Total Diagnosed Prevalent Cases
  • Type-specific Diagnosed Prevalent Cases
  • Total Diagnosed Prevalent Cases


Progressive Pulmonary Fibrosis Epidemiological Insights Observed in the 7MM (2021)

The total number of incident cases of Progressive Pulmonary Fibrosis observed in the 7MM was observed to be 128K in the year 2021.


Progressive Pulmonary Fibrosis Market Insight

The market size of Progressive Pulmonary Fibrosis in the 7MM was found to be approximately USD 891 million in 2021.


Progressive Pulmonary Fibrosis Market Strengths

The increasing prevalent population of PPF worldwide due to delay in accurate diagnosis and unavailability of curative treatment options for ILDs are likely to cause a greater need for treatment options. Consequently, the revenue market may witness a boost in the upcoming years.


Progressive Pulmonary Fibrosis Market Opportunities

The shortfall of curative therapies with lesser side effects might provide good space for emerging therapies in the market as currently approved therapy lacks the option to reverse the disease and also has associated side-effects.


Progressive Pulmonary Fibrosis Emerging Drugs and Key Companies


  • BI 1015550: Boehringer Ingelheim, and others